Oklahoma Breakthrough Therapy Act Signed Into Law

Oklahoma Breakthrough Therapy Act Signed Into Law

A groundbreaking new law known as the Oklahoma Breakthrough Therapy Act is officially reshaping Oklahoma’s approach to addiction treatment, PTSD research, and psychedelic-assisted medical therapies.

Governor Kevin Stitt signed House Bill 3834 into law, creating a state-regulated framework allowing clinical trials involving ibogaine, a powerful psychedelic compound derived from the iboga shrub native to Central Africa.

According to the Oklahoma State Department of Health, the new Oklahoma Breakthrough Therapy Act is designed to establish tightly controlled medical research programs focused on addiction recovery, traumatic brain injuries, and severe mental health conditions.

The legislation marks a major policy shift for Oklahoma by moving away from strict drug prohibition toward state-monitored medical research initiatives.

Oklahoma Breakthrough Therapy Act Focuses On Ibogaine Research

The centerpiece of the Oklahoma Breakthrough Therapy Act involves clinical trials using ibogaine, a psychoactive substance that remains federally classified as a Schedule I controlled substance.

According to the National Institute on Drug Abuse, early observational research involving ibogaine has shown potential in treating opioid addiction, substance abuse disorders, PTSD, and traumatic brain injuries.

Under the new law, the Oklahoma State Department of Health can directly partner with pharmaceutical developers and research organizations to conduct multi-state clinical trials physically based in Oklahoma.

The law also establishes the Ibogaine Development Revolving Fund, which will hold future state allocations, donations, and possible federal grants tied to the research initiative.

Oklahoma Breakthrough Therapy Act Includes Strict Safeguards

Supporters of the Oklahoma Breakthrough Therapy Act say the law includes multiple safeguards designed to tightly regulate research and patient protections.

Drug developers working with Oklahoma must match state financial investments dollar-for-dollar under the framework established by House Bill 3834.

According to the U.S. Food and Drug Administration, any eventual commercialization of medications developed through the trials would still require formal FDA approval before broader public distribution.

The law also grants legal protections for participating healthcare professionals administering ibogaine strictly within approved clinical trial settings.

Additionally, any successful treatments developed through the Oklahoma framework must prioritize access for Oklahoma residents.

Supporters And Critics Debate New Psychedelic Research Law

The Oklahoma Breakthrough Therapy Act received strong support from advocacy groups including Veteran Solutions and the Inter-Tribal Council of the Five Civilized Tribes.

Supporters argue traditional addiction and mental health treatment systems continue failing veterans, law enforcement officers, and trauma survivors struggling with severe conditions.

However, critics caution that ibogaine use still carries significant cardiac safety risks and should never occur outside strict medical supervision.

Others argue Oklahoma should simultaneously invest in housing, healthcare access, and long-term social support programs alongside experimental medical research initiatives.

The new law officially takes effect November 1, 2026.

🔴 MORE RADIO NEWS